CERTL reduces C16 ceramide, amyloid-β levels, and inflammation in a model of Alzheimer's disease.

Simone M CrivelliQian LuoJo A A StevensCaterina GiovagnoniDaan van KruiningGerard BodeSandra den HoedtBarbara HoboAnna-Lena ScheithauerJochen WalterMonique T MulderChristopher ExleyMatthew MoldMichelle M MielkeHelga E De VriesKristiaan WoutersDaniel L A van den HoveDusan BerkesMaría Dolores LedesmaJoost VerhaagenMario LosenErhard BieberichPilar Martinez-Martinez

Published in: Alzheimer's research & therapy (2021)

Our results demonstrate a crucial role of CERTL in regulating ceramide levels in the brain, in amyloid plaque formation and neuroinflammation, thereby opening research avenues for therapeutic targets of AD and other neurodegenerative diseases.

Keyphrases

oxidative stress
traumatic brain injury
coronary artery disease
cerebral ischemia
resting state
lipopolysaccharide induced
white matter
cognitive impairment
multiple sclerosis
functional connectivity
inflammatory response
brain injury
subarachnoid hemorrhage